v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jan. 31, 2019
Oct. 31, 2018
Current assets:    
Cash and cash equivalents $ 4,152,638 $ 3,055,890
Short-term investments in certificates of deposit 1,750,000 2,000,000
Prepaid expenses and other current assets 333,671 482,482
Total current assets 6,236,309 5,538,372
Patents, net of impairment of $1,001,729 and $582,979, respectively, and accumulated amortization of $1,866,882 and $1,615,632, respectively 167,500 837,500
Property and equipment, net of accumulated depreciation of $59,929 and $53,799, respectively 66,540 72,670
Total assets 6,470,349 6,448,542
Current liabilities:    
Accounts payable 612,940 582,012
Accrued expenses 714,139 683,099
Total current liabilities 1,327,079 1,265,111
Commitments and contingencies (Note 9)
Shareholders’ equity:    
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Common stock, par value $.01 per share; 48,000,000 shares authorized; 19,470,235 and 18,908,632 shares issued and outstanding, respectively 194,702 189,086
Additional paid-in capital 180,336,763 175,415,931
Accumulated deficit (175,052,050) (170,170,209)
Total shareholders’ equity 5,479,415 5,434,808
Noncontrolling interest (Note 1) (336,145) (251,377)
Total equity 5,143,270 5,183,431
Total liabilities and equity 6,470,349 6,448,542
Series A Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding
Preferred Stock [Member]    
Shareholders’ equity:    
Preferred stock, par value $100 per share; 19,860 shares authorized; no shares issued or outstanding, Series A convertible preferred stock, par value $100 per share; 140 shares authorized; no shares issued or outstanding

Source

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Jan. 31, 2019
Jan. 31, 2018
Revenue
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion 25,353
Amortization of patents 251,250 81,324
Research and development expenses (including non-cash share-based compensation expenses of $1,573,779 and $40,057, respectively) 2,247,272 777,873
General and administrative expenses (including non-cash share-based compensation expenses of $1,176,385 and $226,916, respectively) 2,066,456 990,036
Impairment in carrying amount of patent asset (Note 1) 418,750
Total operating costs and expenses 4,983,728 1,874,586
Loss from operations (4,983,728) (1,874,586)
Interest income 17,119 9,112
Loss before income taxes (4,966,609) (1,865,474)
Provision for income taxes
Net loss (4,966,609) (1,865,474)
Less: Net loss attributable to noncontrolling interest (84,768) (27,402)
Net loss attributable to common shareholders $ (4,881,841) $ (1,838,072)
Net loss per common share attributable to common shareholders:    
Basic and diluted (in Dollars per share) $ (0.25) $ (0.11)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 19,170,591 16,610,770

Source

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
3 Months Ended
Jan. 31, 2019
Jan. 31, 2018
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (4,966,609) $ (1,865,474)
Stock option compensation to employees and directors 1,219,560 214,427
Stock options and warrants issued to consultants 46,219 52,546
Restricted stock award compensation to employee pursuant to stock incentive plan 1,484,385
Common stock issued to consultants 15,002
Depreciation of property and equipment 6,130 4,391
Amortization of patents 251,250 81,324
Impairment in carrying amount of patent assets 418,750
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee 64,656
Change in operating assets and liabilities:    
Prepaid expenses and other current assets 148,811 (103,930)
Accounts payable 30,928 (63,399)
Accrued expenses 31,040 260,464
Net cash used in operating activities (1,329,536) (1,339,993)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (1,250,000)
Proceeds from maturities of short-term investments in certificates of deposit 250,000 2,100,000
Purchase of property and equipment (2,518)
Net cash provided by investing activities 250,000 847,482
Cash flows from financing activities:    
Net proceeds from sale of common stock in at-the-market offering 2,153,584
Proceeds from exercise of employee stock options 22,700
Net cash provided by financing activities 2,176,284
Net increase (decrease) in cash and cash equivalents 1,096,748 (492,511)
Cash and cash equivalents at beginning of period 3,055,890 3,339,374
Cash and cash equivalents at end of period $ 4,152,638 $ 2,846,863

Source